A Markov Model-Based Cost-Effectiveness Analysis Comparing Zanubrutinib to Ibrutinib for Treating Relapsed and Refractory Chronic Lymphocytic Leukemia.
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH（2024）
Key words
Ibrutinib,zanubrutinib,cost-effectiveness,pharmacoeconomic evaluation,relapsed refractory chronic lymphocytic leukemia
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined